BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ORIC Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ORIC Pharmaceuticals's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05315700-2662@assetmemo.bio
DTSTAMP:20261121T005452Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enozertinib: Phase 1/2 readout est. (NCT05315700)
DESCRIPTION:Enozertinib\, phase 1/2.\nStudy: Study of ORIC-114 in Patients 
 With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration\nEstimated
  primary completion: June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/enozertinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05315700
URL:https://assetmemo.bio/drug/enozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07723248-10910@assetmemo.bio
DTSTAMP:20261121T005452Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rinzimetostat: Phase 3 readout est. (NCT07723248)
DESCRIPTION:Rinzimetostat\, phase 3\, Prostate Cancer.\nStudy: A Study to L
 earn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients W
 ith mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-
 1)\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rinzimetostat#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07723248
URL:https://assetmemo.bio/drug/rinzimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
